A mind-bending hallucinogen is moving out of the counterculture and into the clinic. The Food and Drug Administration on Friday greenlit the first-ever human clinical trial of an ibogaine derivative in the US, opening the door to testing the psychedelic drug as a potential treatment for alcohol-use disorder. The move comes just days after President Donald Trump signed an executive order aimed at fast-tracking psychedelic research and expanding access for people struggling with mental illness. President Trump signed an executive order on April 18 to ease legal restrictions that have limited research into psychedelics like ibogaine and how they work.…